Loading...
•
Mar 31, 2023
Aldeyra Q1 2023 Earnings Report
Aldeyra reported financial results for Q1 2023 and provided recent corporate highlights.
Key Takeaways
Aldeyra Therapeutics reported a net loss of $15.6 million, or $0.27 per share, for the first quarter of 2023. The company's cash and cash equivalents totaled $165.0 million as of March 31, 2023.
Top-line results are expected from the Phase 2 clinical trial of ADX-2191 in Retinitis Pigmentosa in Q2 2023.
Top-line results are expected from the Phase 2 clinical trial of ADX-629 in Chronic Cough in Q2 2023.
Top-line results are expected from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis in Q2 2023.
Cash and cash equivalents totaled $165.0 million as of March 31, 2023.
Aldeyra
Aldeyra
Forward Guidance
Aldeyra anticipates multiple regulatory and clinical milestones in the coming quarters.
Positive Outlook
- PDUFA dates for ADX-2191 and reproxalap are planned.
- Top-line results are expected from Phase 2 clinical trials in retinitis pigmentosa.
- Top-line results are expected from Phase 2 clinical trials in chronic cough.
- Top-line results are expected from the Phase 3 INVIGORATE-2 trial in allergic conjunctivitis.
- Existing cash and cash equivalents are expected to fund operating expenses into the second half of 2024.